Jupiter Neurosciences, Inc. JUNS 深 沪
交易中 07-28 11:40:59 美东时间
1.6003
-0.020
-1.22%
华盛通- 最 高1.665
- 今 开1.62
- 成交量 3.04万股
- 最 低 1.581
- 昨 收 1.62
- 总市值 5297.62万
- 52周最高 19.51
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 0.51
- 委 比 99.73%
- 总股本 3310.39万
- 历史最高 19.51
- 量 比 0.61
- 振 幅 5.19%
- 历史最低 0.51
- 每 手 1
- 风险率
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Jupiter Neurosciences Highlights JOTROL;
JOTROL™ is currently advancing toward a Phase IIa trial in Parkinson's Disease, following breakthrough preclinical data in a well-established MPTP mouse model that demonstrated meaningful improvements in motor
07-23 20:14
Jupiter Neurosciences Highlights Critical Advancement of JOTROL™ Over Traditional Resveratrol with Breakthrough Bioavailability and CNS-Targeted Science
Jupiter Neurosciences开发的JOTROL™是一种专利的高生物利用度白藜芦醇平台，解决了传统白藜芦醇生物利用度低和胃肠道副作用的问题。该平台已显示比普通白藜芦醇高9倍的生物利用度，且无副作用，可用于治疗帕金森病等中枢神经系统疾病。其消费者产品线Nugevia™预计于2025年第三季度推出，专注于认知健康和抗衰老领域。
07-23 12:00
Jupiter Neurosciences Regains Compliance with Nasdaq Minimum Bid Price Requirement
Jupiter Neurosciences (NASDAQ: JUNS) has regained compliance with Nasdaq's continued listing standard for minimum share price under Rule 5550(a)(2). The Company's common stock maintained an average closing price of at least $1.00 over 13 consecutive days (June 18-July 8, 2025), resolving its non-compliance issue. This milestone was disclosed in a Form 8-K filed on July 10, 2025.
07-10 20:05
Jupiter Neurosciences Approves Executive Bonus Package
Jupiter Neurosciences, Inc. ( ($JUNS) ) just unveiled an update. On July 2, 202...
07-10 04:57
Jupiter Neurosciences Showcases Nugevia™ PWR: Mitochondrial Optimization Supplement Designed to Boost Energy, Endurance, and Recovery
Jupiter Neurosciences, Inc., a clinical-stage pharmaceutical company, launched Nugevia™ PWR, a daily mitochondrial health supplement designed to support cellular energy, endurance, and recovery. PWR combines JOTROL™, a high-bioavailability resveratrol formulation, with NovaSOL® solubilized CoQ10 to enhance mitochondrial function and protect against oxidative stress. Targeting the growing longevity and wellness markets, PWR offers long-term benefi...
06-30 19:15
Jupiter Neurosciences Unveils Nugevia™ GLO: A Breakthrough in Cellular Skin Health, Backed by Patented Pharmaceutical Science
Jupiter Neurosciences introduces Nugevia™ GLO, a scientifically-backed "beauty-from-within" supplement targeting the booming longevity market. Combining JOTROL™ resveratrol technology and NovaSOL® Astaxanthin, GLO enhances skin vitality by promoting cellular defense, collagen production, and hydration. Priced as a premium product, it appeals to women over 35 seeking evidence-based skin and aging solutions. GLO, launching Fall 2025, is part of Jup...
06-27 12:00
Jupiter Neurosciences Names Golf Legend Annika Sörenstam as First Nugevia™ Brand Ambassador
Jupiter Neurosciences has appointed Annika Sörenstam, the most accomplished female professional golfer in history, as the brand ambassador for its new Nugevia supplement line, which is backed by clinical science and designed to support healthy aging, mental clarity, and cellular vitality. The line uses JOTROL, the Company's patented resveratrol-based delivery system, to enhance bioavailability. Nugevia aims to support cellular resilience and vita...
06-23 12:00
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers Ironwood Pharmaceuticals (NASDAQ:IRWD) stock rose 15.2% to $0.71 durin...
06-14 05:05
Jupiter Neurosciences Commercially Launches Nugevia; First Consumer Products Roll Out In Q3 2025
First consumer products roll out in Q3 2025, creating near-term revenue potential and marking a new chapter in Jupiter's evolutionJupiter, Florida, June 09, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc.
06-09 19:13
Jupiter Neurosciences Launches Nugevia™: A Premium Longevity and Performance Supplement Line Grounded in Clinical Science
Jupiter Neurosciences, Inc. announced the official launch of Nugevia™, its consumer longevity product line, in Q3 2025. This launch marks a strategic milestone for the Company, generating near-term revenue while advancing its clinical pipeline. The products leverage Jupiter's proprietary JOTROL™ micellar delivery technology, which enhances resveratrol bioavailability, addressing its historical challenges. Nugevia’s initial lineup includes formula...
06-09 11:00
